Table of Contents Author Guidelines Submit a Manuscript
Journal of Ophthalmology
Volume 2017, Article ID 4853905, 5 pages
https://doi.org/10.1155/2017/4853905
Research Article

The Influence of Juvenile Graves’ Ophthalmopathy on Graves’ Disease Course

Eye Clinic of Lithuanian University of Health Sciences, Kaunas, Lithuania

Correspondence should be addressed to Jurate Jankauskiene; moc.liamg@ksuaknaj.ruj

Received 2 May 2017; Revised 26 September 2017; Accepted 16 October 2017; Published 31 October 2017

Academic Editor: Neil Lagali

Copyright © 2017 Jurate Jankauskiene and Dalia Jarusaitiene. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. E. Krassas and A. Gogakos, “Thyroid-associated ophthalmopathy in juvenile Graves’ disease–clinical, endocrine and therapeutic aspects,” Journal of Pediatric Endocrinology & Metabolism, vol. 19, no. 10, pp. 1193–1206, 2006. View at Publisher · View at Google Scholar
  2. S. H. Lee, S. Y. Lee, H. R. Chung et al., “Remission rate and remission predictors of Graves’ disease in children and adolescents,” Korean Journal of Pediatrics, vol. 52, no. 9, pp. 1021–1028, 2009. View at Publisher · View at Google Scholar
  3. S. A. Rivkees, “Treatment of hyperthyroidism due to Graves’ disease in children,” in Diseases of the Thyroid in Childhood and Adolescence, G. E. Krassas, S. A. Rivkees, and W. Kiess, Eds., pp. 169–191, Karger, Basel, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Williamson and S. A. Greene, “Incidence of thyrotoxicosis in childhood: a national population based study in the UK and Ireland,” Clinical Endocrinology, vol. 72, no. 3, pp. 358–363, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. O. M. Acuna, I. Athannassaki, and E. A. Paysse, “Association between thyroid-stimulating immunoglobulin levels and ocular findings in pediatric patients with Graves’ disease,” Transactions of the American Ophthalmological Society, vol. 105, pp. 146–150, 2007. View at Google Scholar
  6. T. Diana, R. S. Brown, A. Bossowski et al., “Clinical relevance of thyroid-stimulating autoantibodies in pediatric Graves’ disease – a multicenter study,” The Journal of Clinical Endocrinology and Metabolism, vol. 99, no. 5, pp. 1648–1655, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. S. M. Goldstein, W. R. Katowitz, T. Moshang, and J. A. Katowitz, “Pediatric thyroid-associated orbitopathy: the Children’s Hospital of Philadelphia experience and literature review,” Thyroid, vol. 18, no. 9, pp. 997–999, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. G. E. Krassas, “Childhood Graves’ orbitopathy,” in Graves’ Orbitopathy: A Multidisciplinary Approach, W. M. Wiersinga and G. J. Kahaly, Eds., pp. 239–247, Karger, Basel, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. L. Liu, H. Lu, Y. Liu, C. Liu, and C. Xun, “Predicting relapse of Graves’ disease following treatment with antithyroid drugs,” Experimental and Therapeutic Medicine, vol. 11, no. 4, pp. 1453–1458, 2016. View at Publisher · View at Google Scholar · View at Scopus
  10. B. Quadbeck, R. Hoermann, U. Roggenbuck, S. Hahn, K. Mann, and O. E. Janssen, “Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves’ disease,” Thyroid, vol. 15, no. 9, pp. 1047–1054, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Léger, G. Gelwane, F. Kaguelidou, M. Benmerad, C. Alberti, and French Childhood Graves’ Disease Study Group, “Positive impact of long-term antithyroid drug treatment on the outcome of children with Graves’ disease: national long-term cohort study,” The Journal of Clinical Endocrinology and Metabolism, vol. 97, no. 1, pp. 110–119, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. S. M. Song, J. S. Youn, J. M. Ko, C. K. Cheon, J. H. Choi, and H. W. Yoo, “The natural history and prognostic factors of Graves’ disease in Korean children and adolescents,” Korean Journal of Pediatrics, vol. 53, no. 4, pp. 585–591, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. H. Ohye, A. Minagawa, J. Y. Noh et al., “Antithyroid drug treatment for Graves’ disease in children: a long-term retrospective study at a single institution,” Thyroid, vol. 24, no. 2, pp. 200–207, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. S. M. Kim and J. S. Hwang, “Remission predictors of Graves’ disease in children,” Journal of Korean Society of Pediatric Endocrinology, vol. 15, pp. 100–105, 2010. View at Google Scholar
  15. R. Gastaldi, E. Poggi, A. Mussa et al., “Graves disease in children: thyroid-stimulating hormone receptor antibodies as remission markers,” The Journal of Pediatrics, vol. 164, no. 5, pp. 1189–1194.e1, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. F. Kaguelidou, C. Alberti, M. Castanet et al., “Predictors of autoimmune hyperthyroidism relapse in children after discontinuation of antithyroid drug treatment,” The Journal of Clinical Endocrinology and Metabolism, vol. 93, no. 10, pp. 3817–3826, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. E. Mohlin, H. Filipsson Nyström, and M. Eliasson, “Long-term prognosis after medical treatment of Graves’ disease in a northern Swedish population 2000–2010,” European Journal of Endocrinology, vol. 170, no. 3, pp. 419–427, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. P. Anagnostis, F. Adamidou, S. A. Polyzos et al., “Predictors of long-term remission in patients with Graves’ disease: a single center experience,” Endocrine, vol. 44, no. 2, pp. 448–453, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. A. K. Eckstein, M. Plicht, H. Lax et al., “Thyrotropin receptor autoantibodies are independent risk factors for Graves’ ophthalmopathy and help to predict severity and outcome of the disease,” The Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 9, pp. 3464–3470, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. P. Vitti, T. Rago, L. Chiovato et al., “Clinical features of patients with Graves’ disease undergoing remission after antithyroid drug treatment,” Thyroid, vol. 7, no. 3, pp. 369–375, 1997. View at Publisher · View at Google Scholar
  21. G. Benker, D. Reinwein, G. Kahaly et al., “Is there a methimazole dose effect on remission rate in graves’ disease? Results from a long-term prospective study. The European Multicentre Trial Group of the Treatment of Hyperthyroidism with Antithyroid Drugs,” Clinical Endocrinology, vol. 49, no. 4, pp. 451–457, 1998. View at Publisher · View at Google Scholar · View at Scopus
  22. M. P. Mourits, M. F. Prummel, W. M. Wiersinga, and L. Koornneef, “Clinical activity score as a guide in the management of patients with Graves’ ophthalmopathy,” Clinical Endocrinology, vol. 47, no. 1, pp. 9–14, 1997. View at Publisher · View at Google Scholar
  23. L. Bartalena, L. Baldeschi, A. J. Dickinson et al., “Consensus statement of the European group on Graves’ orbitopathy (EUGOGO) on management of Graves’ orbitopathy,” Thyroid, vol. 18, no. 3, pp. 333–346, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. D. Jarusaitiene, J. Lisicova, A. Krucaite, and J. Jankauskiene, “Exophthalmometry value distribution in healthy Lithuanian children and adolescents,” Saudi Journal of Ophthalmology, vol. 30, no. 2, pp. 92–97, 2015. View at Publisher · View at Google Scholar · View at Scopus
  25. B. G. Nedrebo, P. I. Holm, S. Uhlving et al., “Predictors of outcome and comparison of different drug regimens for the prevention of relapse in patients with Graves’ disease,” European Journal of Endocrinology, vol. 147, no. 5, pp. 583–589, 2002. View at Publisher · View at Google Scholar
  26. G. E. Krassas and W. Wiersinga, “Smoking and autoimmune thyroid disease: the plot thickens,” European Journal of Endocrinology, vol. 154, no. 6, pp. 777–780, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. A. Allahabadia, J. Daykin, R. L. Holder, M. C. Sheppard, S. C. Gough, and J. A. Franklyn, “Age and gender predict the outcome of treatment for Graves’ hyperthyroidism,” The Journal of Clinical Endocrinology and Metabolism, vol. 85, no. 3, pp. 1038–1042, 2000. View at Publisher · View at Google Scholar
  28. N. Sawicka-Gutaj, P. Gutaj, J. Sowiński et al., “Influence of cigarette smoking on thyroid gland--an update,” Endokrynologia Polska, vol. 65, no. 1, pp. 54–62, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Kubota, H. Ohye, E. Nishihara et al., “Effect of high dose methylprednisolone pulse therapy followed by oral prednisolone administration on the production of anti-TSH receptor antibodies and clinical outcome in Graves’ disease,” Endocrine Journal, vol. 52, no. 6, pp. 735–741, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. F. Yang, Z. Shan, X. Teng et al., “Chronic iodine excess does not increase the incidence of hyperthyroidism: a prospective community-based epidemiological survey in China,” European Journal of Endocrinology, vol. 156, no. 4, pp. 403–408, 2007. View at Publisher · View at Google Scholar · View at Scopus